VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
PODDInsulet Corporation
$145.76$10.2B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPODDP/E History

PODD logoInsulet Corporation (PODD) P/E Ratio History

Deep Value

Trading at 41.9x · 10th percentile of 5-year range · Significant discount to historical valuation · Data 2018–2026

Current P/E (TTM)
41.9x
-99% vs 5Y avg
5Y Avg P/E
3776.0x
Median 95.5x
5Y Percentile
10th
Lower end of range
PEG Ratio
0.41
Growth supports price
5-Year P/E Range
41.9x
Min36.7xMedian95.5xMax62541.2x
TTM EPS$4.31
Price$145.76
Earnings Yield2.39%
EPS Growth (1Y)-39.8%
EPS Growth (5Y)103.4%

Loading P/E history...

P/E Ratio Analysis

As of June 21, 2026, Insulet Corporation (PODD) trades at a price-to-earnings ratio of 41.9x, with a stock price of $145.76 and trailing twelve-month earnings per share of $4.31.

The current P/E is 99% below its 5-year average of 3776.0x. Over the past five years, PODD's P/E has ranged from a low of 36.7x to a high of 62541.2x, placing the current valuation at the 10th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, PODD trades at a 89% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

The PEG ratio of 0.41 (P/E divided by -40% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, PODD commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PODD DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

PODD Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
41.9vs22.1
+89%
Above Sector
vs. S&P 500
41.9vs24.4
+71%
Above Market
PEG Analysis
0.41
P/E ÷ EPS Growth
PEG < 1 = Attractive
Based on -40% EPS growth (1Y)

PODD P/E vs Peers

Diabetes care and insulin delivery peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
DXCM logoDXCMDexCom, Inc.
$28B34.73.31+47%
ITGR logoITGRInteger Holdings Corporation
$3B31.57.15-15%
ABT logoABTAbbott Laboratories
$154B11.6Lowest0.39Best+134%Best
MDT logoMDTMedtronic plc
$102B22.0-+31%
BDX logoBDXBecton, Dickinson and Company
$52B24.71.49-1%
NVO logoNVONovo Nordisk A/S
$192B12.20.59+2%
LLY logoLLYEli Lilly and Company
$1.0T47.81.66+96%
SNY logoSNYSanofi
$102B18.1--7%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

PODD Historical P/E Data (2018–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1-$209.84$4.3048.8x-98%
FY2025 Q4Dec 31 2025$284.24$3.5081.2x-97%
FY2025 Q3-$308.73$3.4589.5x-97%
FY2025 Q2Jun 30 2025$314.18$3.2995.5x-97%
FY2025 Q1Mar 31 2025$262.61$5.5647.2x-98%
FY2024 Q4-$261.07$5.7945.1x-98%
FY2024 Q3Sep 30 2024$232.75$5.8839.6x-99%
FY2024 Q2Jun 30 2024$201.80$5.5036.7x-99%
FY2024 Q1Mar 31 2024$171.40$3.3051.9x-98%
FY2023 Q4Dec 31 2023$216.98$2.9174.6x-97%
FY2023 Q3Sep 30 2023$159.49$1.6795.5x-97%
FY2023 Q2Jun 30 2023$288.34$0.90322.1x-89%
FY2023 Q1Mar 31 2023$318.96$0.0162541.2x+2012%
FY2022 Q4Dec 31 2022$294.39$0.074522.1x+53%
FY2022 Q3Sep 30 2022$229.40$0.25935.9x-68%
FY2022 Q2-$217.94$0.50435.9x-85%
FY2022 Q1-$266.39$0.63422.8x-86%
FY2021 Q4Dec 31 2021$266.07$0.241112.8x-62%
FY2021 Q1Mar 31 2021$260.92$0.141875.8x-37%
FY2020 Q4-$255.63$0.102646.3x-11%
FY2020 Q3Sep 30 2020$236.59$0.44541.9x-82%
FY2020 Q2-$194.26$0.28702.3x-76%
FY2020 Q1-$165.68$0.082162.9x-27%
FY2019 Q4-$171.20$0.18951.1x-68%
FY2019 Q3Sep 30 2019$164.93$0.26634.3x-79%
FY2019 Q2Jun 30 2019$119.38$0.28426.4x-86%
FY2019 Q1Mar 31 2019$95.09$0.23411.1x-86%
FY2018 Q4Dec 31 2018$79.32$0.051546.2x-48%

Average P/E for displayed period: 2960.6x

Export Data
Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into PODD consensus models and risk factors.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

8+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

PODD — Frequently Asked Questions

Quick answers to the most common questions about buying PODD stock.

What is PODD's P/E ratio?

Insulet Corporation (PODD) trailing twelve-month P/E ratio is 41.9x, based on TTM diluted EPS of $4.31. The 5-year average P/E is 3776.0x and the historical range spans 36.7x to 62541.2x.

Is PODD stock overvalued or undervalued?

PODD trades at 41.9x P/E, below its 5-year average of 3776.0x. At the 10th percentile of its historical range (36.7x–62541.2x), the stock is priced at a discount to its own history.

Is PODD stock expensive?

No, PODD is not expensive on a historical basis. The current P/E of 41.9x is below the 5-year average of 3776.0x and sits at the 10th percentile of its valuation range.

What is PODD's historical P/E range?

Over the past 5 years, PODD's P/E ratio has ranged from 36.7x to 62541.2x, with a median of 95.5x and an average of 3776.0x. The current P/E of 41.9x places the stock at the 10th percentile of this range. Full historical data spans 2018–2026.

How does PODD's P/E compare to the S&P 500?

PODD trades at 41.9x P/E versus the S&P 500 median of 24.4x. The 72% premium to the market typically reflects higher expected earnings growth or quality.

How does PODD's valuation compare to Healthcare peers?

Insulet Corporation P/E of 41.9x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is PODD's PEG ratio?

PODD PEG ratio is 0.41, based on a P/E of 41.9x and EPS growth of -39.8%. A PEG below 1.0 indicates the valuation is supported by the earnings growth rate — typically considered attractive.

What is PODD's earnings yield?

PODD earnings yield is 2.39%, the inverse of its 41.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

PODD P/E Ratio History (2018–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current48.8x
Period Avg3776.0x
Range36.7x - 62541.2x
Change-98%
20 quartersDec 31, 2020 - Mar 31, 2026